Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL

Abstract Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-X L have been recently validated as drug discovery targets for cancer. Here, by using a combination of molecular modeling, NMR-based structural analysis, fluorescence polarization assays, and cell-based assays, we have designed and characterized a novel proapoptotic compound targeting these proteins. Our compound, Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-X L with high affinity and induces apoptosis of tumor cell lines. Mechanistic studies on the action of our compound were also performed via confocal microscopy that provided real-time detection of the interaction with Bcl-X L in intact cells. Finally, preliminary data on cells freshly isolated from patients affected by chronic lymphocytic leukemia strongly suggest potential applications of Bcl-2 antagonists as chemosensitizers in cancer therapy.

[1]  Oliver Zerbe.  BioNMR in drug research , 2003 .

[2]  Ziwei Huang,et al.  Bcl-2 family proteins as targets for anticancer drug design , 2000, Oncogene.

[3]  J Brickmann,et al.  Texture mapping: a new tool for molecular graphics. , 1994, Journal of Molecular Graphics.

[4]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[5]  J. D. Edwards,et al.  Gossypol, a pigment of cottonseed. , 1960, Chemical reviews.

[6]  C. Rudin,et al.  A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia: implications for therapy. , 1998, Seminars in hematology.

[8]  黄建华,et al.  Regioselective bromination and fluorination of apogossypol hexamethyl ether , 1992 .

[9]  R. Knazek,et al.  Oral gossypol in the treatment of metastatic adrenal cancer. , 1993, The Journal of clinical endocrinology and metabolism.

[10]  N. E. Gilbert,et al.  Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. , 1995, Life sciences.

[11]  Stephen W. Fesik,et al.  One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules , 1997 .

[12]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[13]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[14]  John Calvin Reed.  A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation? , 1996, Leukemia research.

[15]  J. Sham,et al.  Cytotoxic effect of gossypol on colon carcinoma cells. , 2000, Life sciences.

[16]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[17]  C. Benz,et al.  Developing gossypol derivatives with enhanced antitumor activity , 2004, Investigational New Drugs.

[18]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[19]  T. R. Seshadri,et al.  AN EFFICIENT METHOD FOR THE PREPARATION OF (+)-APOGOSSYPOL , 1978 .

[20]  John Calvin Reed.  Molecular biology of chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[21]  Dajun Yang,et al.  Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.

[22]  P. Groundwater,et al.  Structure-activity studies on gossypol in tumor cell lines , 2000, Anti-cancer drugs.

[23]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[24]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[25]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[26]  John Calvin Reed.  Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Dandliker,et al.  Equilibrium and kinetic inhibition assays based upon fluorescence polarization. , 1981, Methods in enzymology.

[28]  A. Kudelka,et al.  An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. , 2002, Pharmacological research.

[29]  C. Hudis,et al.  Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial , 2001, Breast Cancer Research and Treatment.

[30]  R. Coombes,et al.  A preliminary clinical study of gossypol in advanced human cancer , 2004, Cancer Chemotherapy and Pharmacology.

[31]  John Calvin Reed,et al.  Apoptosis-based therapies , 2002, Nature Reviews Drug Discovery.

[32]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[33]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[34]  R. Riek,et al.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  L. Levin,et al.  Different Pathways of Cell Killing by Gossypol Enantiomers , 2002, Experimental biology and medicine.

[36]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[37]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[38]  G H Werner,et al.  Synthesis and cytotoxicity of gossypol related compounds. , 2000, European journal of medicinal chemistry.

[39]  J. Martinou,et al.  The Bcl-2 protein family. , 2000, Experimental cell research.

[40]  A. Godzik,et al.  Bcl-G, a Novel Pro-apoptotic Member of the Bcl-2 Family* , 2001, The Journal of Biological Chemistry.

[41]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.